Literature DB >> 11686490

Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats.

L Belayev1, O F Alonso, Y Liu, A S Chappell, W Zhao, M D Ginsberg, R Busto.   

Abstract

Talampanel [(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine] is an orally active noncompetitive antagonist of the AMPA subtype of glutamate excitatory amino acid receptors. The purpose of this study was to determine whether treatment with talampanel would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, a fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and a balance of oxygen; mechanically ventilated and physiologically regulated; and subjected to right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). The agent (talampanel, bolus infusion of 4 mg/kg followed by infusion of 4 mg/kg/h over 72 h) or vehicle was administered i.v. starting at either 30 min or 3 h after trauma. Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas were measured. Treatment with talampanel, when instituted 30 min after trauma, significantly reduced total contusion area compared to vehicle-treated rats (0.54 +/- 0.25 vs. 1.79 +/- 0.42 mm2, respectively). When talampanel treatment was begun at 3 h, the neuroprotective effect of the drug was lost. In addition, treatment with talampanel starting at 30 min significantly attenuated neuronal damage in all three subsectors of the hippocampal CA1 sector compared to vehicle-treated rats (normal-neuron counts, right (ipsilateral) medial CA1: 80.3 +/- 2.0 [talampanel] vs. 66.3 +/- 2.1 [vehicle] (mean +/- SEM); middle CA1: 71.5 +/- 2.0 vs. 60.3 +/- 2.2; lateral CA1: 74.5 +/- 3.0 vs. 63.0 +/- 3.2, respectively). By contrast, when talampanel treatment was begun at 3 h, normal pyramidal-neuron counts were almost identical in both groups. Our findings document that talampanel therapy instituted 30 min after trauma significantly reduces histological damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686490     DOI: 10.1089/08977150152693728

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  15 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Talampanel.

Authors:  John F Howes; Cynthia Bell
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Recovery of network-driven glutamatergic activity in rat hippocampal neurons during chronic glutamate receptor blockade.

Authors:  Eric Leininger; Andrei B Belousov
Journal:  Brain Res       Date:  2008-11-25       Impact factor: 3.252

4.  Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.

Authors:  Simone Brogi; Giuseppe Campiani; Margherita Brindisi; Stefania Butini
Journal:  ACS Med Chem Lett       Date:  2019-01-23       Impact factor: 4.345

Review 5.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

Review 6.  Therapeutic strategies to target acute and long-term sequelae of pediatric traumatic brain injury.

Authors:  Jimmy W Huh; Ramesh Raghupathi
Journal:  Neuropharmacology       Date:  2018-06-20       Impact factor: 5.250

7.  Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion.

Authors:  J Marc Simard; Michael Kilbourne; Orest Tsymbalyuk; Cigdem Tosun; John Caridi; Svetlana Ivanova; Kaspar Keledjian; Grant Bochicchio; Volodymyr Gerzanich
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

8.  Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection.

Authors:  Ivorlyne P Greene; Eun-Young Lee; Natalie Prow; Brownhilda Ngwang; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

9.  The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.

Authors:  Carrie A Keck; Hilaire J Thompson; Asla Pitkänen; David G LeBold; Diego M Morales; Jamie B Plevy; Rishi Puri; Boyu Zhao; Marc Dichter; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

10.  Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model.

Authors:  Paven K Aujla; Michael R Fetell; Frances E Jensen
Journal:  Epilepsia       Date:  2009-02-12       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.